MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

NCT01227941 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: MK-4827 + pegylated liposomal doxorubicin
DRUG: MK-4827 + pegylated liposomal doxorubicin

Sponsor

Tesaro, Inc.